| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.9 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |